P450 (Cytochrome) oxidoreductase gene (POR) common variant (POR∗28) significantly alters CYP2C9 activity in Swedish, but not in Korean healthy subjects

OMICS A Journal of Integrative Biology

Volumn 19, Issue 12, 2015, Pages 777-781

  Hatta, Fazleen H M ^a,b   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450 2C9; CYTOCHROME P450 REDUCTASE; LOSARTAN; CYTOCHROME P450; POR PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME METABOLISM; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; KOREAN (PEOPLE); MALE; METABOLIC RATIO; NORMAL HUMAN; PHARMACOGENETICS; PHENOTYPE; PHENOTYPIC VARIATION; POPULATION GENETICS; PREDICTOR VARIABLE; PRIORITY JOURNAL; SMOKING; SWEDISH CITIZEN; ASIAN CONTINENTAL ANCESTRY GROUP; CAUCASIAN; ENZYME ACTIVATION; GENETICS; METABOLISM; SOUTH KOREA; SWEDEN;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; MALE; REPUBLIC OF KOREA; SWEDEN;

EID: 84951751454     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2015.0159     Document Type: Article

References (26)

1. Adachi M, Asakura Y, Matsuo M, et al. (2006). POR R457H is a global founder mutation causing Antley-Bixler syndrome with autosomal recessive trait. Am J Med Genet A 140, 633-635.
2. De Jonge H, Metalidis C, Naesens M, Lambrechts D, and Kuypers DR. (2011). The P450 oxidoreductase 28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12, 1281-1291.
3. Diczfalusy U, Miura J, Roh H-K, et al. (2008). 4b- Hydroxycholesterol is a new endogenous CYP3A marker: Relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18, 201-208.
4. Fluck CE, Tajima T, Pandey AV, et al. (2004). Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36, 228-230.
5. Gebeyehu E, Engidawork E, Bijnsdorp A, et al. (2011). Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J 11, 130-137.
6. Gomes AM, Winter S, Klein K, et al. (2009). Pharmacogenomics of human liver cytochrome P450 oxidoreductase: Multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10, 579-599.
7. Han EH, Kim HG, Choi JH, et al. (2012). Capsaicin induces CYP3A4 expression via pregnane X receptor and CCAAT/enhancer-binding protein beta activation. Mol Nutr Food Res 56, 797-809.
8. Hart SN, Wang S, Nakamoto K, et al. (2008). Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 18, 11-24.
9. Hatta FH, Lundblad M, Ramsjo M, et al. (2015). Differences in CYP2C9 genotype and enzyme activity between Swedes and Koreans of relevance for personalized medicine: Role of ethnicity, genotype, smoking, age, and sex. OMICS 19, 346-353.
10. Hatta FH, Teh LK, Hellden A, et al. (2012). Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: Relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes. Eur J Clin Pharmacol 68, 1033-1042.
11. Hidaka M, Nagata M, Kawano Y, et al. (2008). Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro. Biosci Biotechnol Biochem 72, 406-411.
12. Higdon R, Earl RK, Stanberry L, et al. (2015). The promise of multi-omics and clinical data integration to identify and target personalized healthcare approaches in autism spectrum disorders. OMICS 19, 197-208.
13. Huang N, Agrawal V, Giacomini KM, and Miller WL. (2008). Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 105, 1733-1738.
14. Huang N, Pandey AV, Agrawal V, et al. (2005). Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76, 729-749.
15. Kimura Y, Ito H, and Hatano T. (2010). Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity. Biol Pharm Bull 33, 1977-1982.
16. Masters BS. (2005). The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. Biochem Biophys Res Commun 338, 507-519.
17. Oneda B, Crettol S, Jaquenoud Sirot E, et al. (2009). The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 19, 877-883.
18. Riddick DS, Ding X, Wolf CR, et al. (2013). NADPHcytochrome P450 oxidoreductase: Roles in physiology, pharmacology, and toxicology. Drug Metab Dispos 41, 12-23.
19. Sandberg M, Johansson I, Christensen M, Rane A, and Eliasson E. (2004). The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 32, 484-489.
20. Sandee D, Morrissey K, Agrawal V, et al. (2010). Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 20, 677-686.
21. Si D, Wang Y, Zhou YH, et al. (2009). Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos 37, 629-634.
22. Srinivas NR. (2013). Cranberry juice ingestion and clinical drug-drug interaction potentials; Review of case studies and perspectives. J Pharm Pharm Sci 16, 289-303.
23. Subramanian M, Agrawal V, Sandee D, et al. (2012). Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics 22, 590-597.
24. The Genomes Project C. (2012). An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65.
25. Tomalik-Scharte D, Maiter D, Kirchheiner J, et al. (2010). Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol 163, 919-924.
26. Yasar U, Forslund-Bergengren C, Tybring G, et al. (2002). Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71, 89-98.